Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field ...

Bruce Power's Chief Operating Officer James Scongack is also Chairman of the Canadian Nuclear Isotope Council and, as he ...

Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival ...

Swiss drugmaker Novartis predicted that the Australian government would not defend its nuclear medicine world technology ...

Scientists from Tomsk Polytechnic University, in collaboration with their colleagues, supported by the federal Priority-2030 ...

The FDA has completed its review of the investigational new drug application (IND) for PSV359, and issued a "study may proceed” letter in 1Q 2025. Site activation activities are underway, with the ...

As State-owned South African Nuclear Energy Corporation (Necsa) marks the sixtieth anniversary of its SAFARI-1 research ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

The Asia-Pacific nuclear medicine market was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 million by 2028, registering a CAGR of 10.4% from 2021 to 2028. The market is ...

Seoul National University Hospital has surpassed 1,500 cases of radiation embolization, achieving the highest number of procedures in Asia. Starting with the first radiation embolization in 2011, the ...